Switch to:
Also traded in: Germany, Japan

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.77
TKPYY's Cash to Debt is ranked higher than
94% of the 766 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.99 vs. TKPYY: 0.77 )
Ranked among companies with meaningful Cash to Debt only.
TKPYY' s Cash to Debt Range Over the Past 10 Years
Min: 0.7  Med: 38.39 Max: N/A
Current: 0.77
Equity to Asset 0.47
TKPYY's Equity to Asset is ranked lower than
73% of the 688 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. TKPYY: 0.47 )
Ranked among companies with meaningful Equity to Asset only.
TKPYY' s Equity to Asset Range Over the Past 10 Years
Min: 0.47  Med: 0.55 Max: 0.76
Current: 0.47
0.47
0.76
Interest Coverage 7.43
TKPYY's Interest Coverage is ranked lower than
76% of the 622 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 96.24 vs. TKPYY: 7.43 )
Ranked among companies with meaningful Interest Coverage only.
TKPYY' s Interest Coverage Range Over the Past 10 Years
Min: 3.18  Med: 189.06 Max: 1856.28
Current: 7.43
3.18
1856.28
F-Score: 6
Z-Score: 2.53
M-Score: -2.49
WACC vs ROIC
4.91%
7.76%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 13.05
TKPYY's Operating margin (%) is ranked higher than
65% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.72 vs. TKPYY: 13.05 )
Ranked among companies with meaningful Operating margin (%) only.
TKPYY' s Operating margin (%) Range Over the Past 10 Years
Min: -7.27  Med: 18.74 Max: 35.13
Current: 13.05
-7.27
35.13
Net-margin (%) 8.64
TKPYY's Net-margin (%) is ranked higher than
61% of the 715 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.96 vs. TKPYY: 8.64 )
Ranked among companies with meaningful Net-margin (%) only.
TKPYY' s Net-margin (%) Range Over the Past 10 Years
Min: -8.2  Med: 12.39 Max: 25.85
Current: 8.64
-8.2
25.85
ROE (%) 7.65
TKPYY's ROE (%) is ranked higher than
52% of the 744 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.03 vs. TKPYY: 7.65 )
Ranked among companies with meaningful ROE (%) only.
TKPYY' s ROE (%) Range Over the Past 10 Years
Min: -6.33  Med: 8.85 Max: 15.12
Current: 7.65
-6.33
15.12
ROA (%) 3.81
TKPYY's ROA (%) is ranked higher than
51% of the 773 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.68 vs. TKPYY: 3.81 )
Ranked among companies with meaningful ROA (%) only.
TKPYY' s ROA (%) Range Over the Past 10 Years
Min: -3.29  Med: 6.12 Max: 12
Current: 3.81
-3.29
12
ROC (Joel Greenblatt) (%) 42.75
TKPYY's ROC (Joel Greenblatt) (%) is ranked higher than
82% of the 762 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.24 vs. TKPYY: 42.75 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
TKPYY' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -19.36  Med: 48.9 Max: 207.72
Current: 42.75
-19.36
207.72
Revenue Growth (3Y)(%) 5.20
TKPYY's Revenue Growth (3Y)(%) is ranked lower than
51% of the 601 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.60 vs. TKPYY: 5.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
TKPYY' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0.2  Med: 5.05 Max: 11.6
Current: 5.2
0.2
11.6
EBITDA Growth (3Y)(%) -4.40
TKPYY's EBITDA Growth (3Y)(%) is ranked lower than
72% of the 555 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.00 vs. TKPYY: -4.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
TKPYY' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -28.3  Med: -1.15 Max: 24.8
Current: -4.4
-28.3
24.8
EPS Growth (3Y)(%) -18.50
TKPYY's EPS Growth (3Y)(%) is ranked lower than
79% of the 520 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.20 vs. TKPYY: -18.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
TKPYY' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -24.5  Med: -0.8 Max: 31.4
Current: -18.5
-24.5
31.4
» TKPYY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with TKPYY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:NAS:MYL, NYSE:ZTS, NYSE:TEVA, OTCPK:ESALY, OTCPK:SGIOF, OTCPK:MKGAY, NYSE:PRGO, OTCPK:APNHF, OTCPK:MTZPY, NYSE:VRX, NYSE:MNK, OTCPK:HLUYY, NYSE:RDY, OTCPK:HKMPF, OTCPK:MDABY, NYSE:TARO, OTCPK:HYPMY, NAS:OPK, NAS:ENDP, NAS:NBIX » details
Traded in other countries:TKD.Germany, 4502.Japan,
Takeda Pharmaceutical Co Ltd is engaged in the manufacturing, marketing and import and export of pharmaceutical drugs.

Takeda Pharmaceutical Co Ltd was founded on June 12, 1781 and was incorporated on January 29, 1925. The Company is primarily engaged in the any manufacture and sale of pharmaceuticals, food supplements, and chemical products such as polyurethane. The Company also produces food, agrochemicals, and environment-related products such as pollution detectors. It is also engaged in the research, development, and promotion of its products through its related companies in the US, Europe, and Asia.

Ratios

vs
industry
vs
history
P/E(ttm) 22.54
TKPYY's P/E(ttm) is ranked higher than
61% of the 533 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.83 vs. TKPYY: 22.54 )
Ranked among companies with meaningful P/E(ttm) only.
TKPYY' s P/E(ttm) Range Over the Past 10 Years
Min: 6.52  Med: 19.34 Max: 90.66
Current: 22.54
6.52
90.66
Forward P/E 25.45
TKPYY's Forward P/E is ranked lower than
65% of the 65 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.21 vs. TKPYY: 25.45 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 22.54
TKPYY's PE(NRI) is ranked higher than
61% of the 533 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.53 vs. TKPYY: 22.54 )
Ranked among companies with meaningful PE(NRI) only.
TKPYY' s PE(NRI) Range Over the Past 10 Years
Min: 6.52  Med: 19.34 Max: 90.66
Current: 22.54
6.52
90.66
Price/Owner Earnings (ttm) 34.21
TKPYY's Price/Owner Earnings (ttm) is ranked higher than
51% of the 278 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 36.03 vs. TKPYY: 34.21 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
TKPYY' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 11.64  Med: 45.32 Max: 581.3
Current: 34.21
11.64
581.3
P/B 1.94
TKPYY's P/B is ranked higher than
65% of the 716 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.95 vs. TKPYY: 1.94 )
Ranked among companies with meaningful P/B only.
TKPYY' s P/B Range Over the Past 10 Years
Min: 1.22  Med: 1.54 Max: 2.44
Current: 1.94
1.22
2.44
P/S 1.97
TKPYY's P/S is ranked higher than
62% of the 692 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.72 vs. TKPYY: 1.97 )
Ranked among companies with meaningful P/S only.
TKPYY' s P/S Range Over the Past 10 Years
Min: 1.67  Med: 2.2 Max: 12.29
Current: 1.97
1.67
12.29
PFCF 39.35
TKPYY's PFCF is ranked lower than
67% of the 188 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.56 vs. TKPYY: 39.35 )
Ranked among companies with meaningful PFCF only.
TKPYY' s PFCF Range Over the Past 10 Years
Min: 10.03  Med: 42.6 Max: 204.92
Current: 39.35
10.03
204.92
POCF 27.56
TKPYY's POCF is ranked lower than
69% of the 249 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.62 vs. TKPYY: 27.56 )
Ranked among companies with meaningful POCF only.
TKPYY' s POCF Range Over the Past 10 Years
Min: 7.75  Med: 37.45 Max: 69.13
Current: 27.56
7.75
69.13
EV-to-EBIT 14.87
TKPYY's EV-to-EBIT is ranked higher than
79% of the 523 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.84 vs. TKPYY: 14.87 )
Ranked among companies with meaningful EV-to-EBIT only.
TKPYY' s EV-to-EBIT Range Over the Past 10 Years
Min: -47.1  Med: 10.6 Max: 46.2
Current: 14.87
-47.1
46.2
EV-to-EBITDA 10.03
TKPYY's EV-to-EBITDA is ranked higher than
86% of the 552 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.38 vs. TKPYY: 10.03 )
Ranked among companies with meaningful EV-to-EBITDA only.
TKPYY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 3.3  Med: 11.2 Max: 2171.3
Current: 10.03
3.3
2171.3
Shiller P/E 9.39
TKPYY's Shiller P/E is ranked higher than
94% of the 154 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 51.85 vs. TKPYY: 9.39 )
Ranked among companies with meaningful Shiller P/E only.
TKPYY' s Shiller P/E Range Over the Past 10 Years
Min: 8.73  Med: 9.57 Max: 10.16
Current: 9.39
8.73
10.16
Current Ratio 1.79
TKPYY's Current Ratio is ranked lower than
63% of the 675 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.39 vs. TKPYY: 1.79 )
Ranked among companies with meaningful Current Ratio only.
TKPYY' s Current Ratio Range Over the Past 10 Years
Min: 1.21  Med: 2.21 Max: 4
Current: 1.79
1.21
4
Quick Ratio 1.50
TKPYY's Quick Ratio is ranked lower than
59% of the 675 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.78 vs. TKPYY: 1.50 )
Ranked among companies with meaningful Quick Ratio only.
TKPYY' s Quick Ratio Range Over the Past 10 Years
Min: 1  Med: 1.84 Max: 3.64
Current: 1.5
1
3.64
Days Inventory 174.98
TKPYY's Days Inventory is ranked lower than
76% of the 673 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.20 vs. TKPYY: 174.98 )
Ranked among companies with meaningful Days Inventory only.
TKPYY' s Days Inventory Range Over the Past 10 Years
Min: 132.84  Med: 162.63 Max: 180.99
Current: 174.98
132.84
180.99

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.57
TKPYY's Dividend Yield is ranked higher than
88% of the 604 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.56 vs. TKPYY: 3.57 )
Ranked among companies with meaningful Dividend Yield only.
TKPYY' s Dividend Yield Range Over the Past 10 Years
Min: 2.71  Med: 4.51 Max: 6.48
Current: 3.57
2.71
6.48
Dividend Payout 0.94
TKPYY's Dividend Payout is ranked lower than
89% of the 373 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.34 vs. TKPYY: 0.94 )
Ranked among companies with meaningful Dividend Payout only.
TKPYY' s Dividend Payout Range Over the Past 10 Years
Min: 0.16  Med: 0.92 Max: 7.35
Current: 0.94
0.16
7.35
Forward Dividend Yield 3.88
TKPYY's Forward Dividend Yield is ranked higher than
87% of the 589 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.60 vs. TKPYY: 3.88 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 3.57
TKPYY's Yield on cost (5-Year) is ranked higher than
77% of the 715 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.13 vs. TKPYY: 3.57 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
TKPYY' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 2.71  Med: 4.51 Max: 6.48
Current: 3.57
2.71
6.48
3-Year Average Share Buyback Ratio 0.30
TKPYY's 3-Year Average Share Buyback Ratio is ranked higher than
86% of the 425 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.60 vs. TKPYY: 0.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
TKPYY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -0.3  Med: 0 Max: 3.9
Current: 0.3
-0.3
3.9

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 7.89
TKPYY's Price/Tangible Book is ranked lower than
77% of the 671 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.60 vs. TKPYY: 7.89 )
Ranked among companies with meaningful Price/Tangible Book only.
TKPYY' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.85  Med: 6.96 Max: 13.07
Current: 7.89
1.85
13.07
Price/Projected FCF 1.78
TKPYY's Price/Projected FCF is ranked higher than
61% of the 304 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.53 vs. TKPYY: 1.78 )
Ranked among companies with meaningful Price/Projected FCF only.
TKPYY' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.14  Med: 1.42 Max: 2.13
Current: 1.78
1.14
2.13
Price/Median PS Value 0.89
TKPYY's Price/Median PS Value is ranked higher than
73% of the 653 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.15 vs. TKPYY: 0.89 )
Ranked among companies with meaningful Price/Median PS Value only.
TKPYY' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.81  Med: 1.01 Max: 5.17
Current: 0.89
0.81
5.17
Price/Graham Number 2.81
TKPYY's Price/Graham Number is ranked lower than
60% of the 411 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.33 vs. TKPYY: 2.81 )
Ranked among companies with meaningful Price/Graham Number only.
TKPYY' s Price/Graham Number Range Over the Past 10 Years
Min: 0.67  Med: 2.51 Max: 4.79
Current: 2.81
0.67
4.79
Earnings Yield (Greenblatt) (%) 6.76
TKPYY's Earnings Yield (Greenblatt) (%) is ranked higher than
85% of the 741 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. TKPYY: 6.76 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
TKPYY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 2.2  Med: 7.4 Max: 23.8
Current: 6.76
2.2
23.8
Forward Rate of Return (Yacktman) (%) -35.06
TKPYY's Forward Rate of Return (Yacktman) (%) is ranked lower than
96% of the 330 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.82 vs. TKPYY: -35.06 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
TKPYY' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -46.9  Med: -16.3 Max: 15.8
Current: -35.06
-46.9
15.8

More Statistics

Revenue (TTM) (Mil) $15,618
EPS (TTM) $ 0.88
Beta0.34
Short Percentage of Float0.00%
52-Week Range $20.32 - 25.72
Shares Outstanding (Mil)1,567.23

Analyst Estimate

Mar17 Mar18
Revenue (Mil $) 17,010 18,166
EPS ($) 0.88 1.15
EPS w/o NRI ($) 0.88 1.15
EPS Growth Rate
(3Y to 5Y Estimate)
3.14%
Dividends Per Share ($) 0.90 0.90
» More Articles for TKPYY

Headlines

Articles On GuruFocus.com
Seth Klarman Buys Pharmaceutical Company's Shares to Fund Drug Launch Oct 12 2015 
5 Popular Asian Stocks Held By the Gurus Apr 16 2015 
Don't Quit on Teva Just Yet Feb 20 2014 
Soros´ Bet on Teva’s Transition (A Transition for Better or for Worse?) Dec 18 2013 
T. Rowe Price Japan Fund Top 5 New Buys Oct 17 2013 

More From Other Websites
AbbVie Expects Investigational Drug Elagolix to Be a Blockbuster Aug 26 2016
Takeda Announces Bold, New Access to Medicines Strategy Aug 26 2016
ETF’s with exposure to Takeda Pharmaceutical Co., Ltd. : August 24, 2016 Aug 24 2016
Hitachi, Carlyle, Permira among bidders for $1 billion Takeda unit - sources Aug 17 2016
Hitachi, Carlyle, Permira among bidders for $1 bln Takeda unit-sources Aug 17 2016
Takeda Receives Marketing Authorization in Canada for NINLARO™ (ixazomib) in Relapsed/Refractory... Aug 08 2016
Takeda Pharmaceutical Co., Ltd. :TKPYY-US: Earnings Analysis: Q1, 2017 By the Numbers : August 5,... Aug 05 2016
Carlyle could make a pair of $2 billion acquisitions in Japan: executive Aug 02 2016
Carlyle could make a brace of $2 bln acquisitions in Japan - exec Aug 02 2016
Takeda and TiGenix Announce Publication in The Lancet of 24-Week Results of the Phase 3 ADMIRE-CD... Aug 02 2016
Takeda and Seattle Genetics Announce Positive Data from Phase 3 ALCANZA Clinical Trial of ADCETRIS®... Aug 01 2016
ETF’s with exposure to Takeda Pharmaceutical Co., Ltd. : July 29, 2016 Jul 29 2016
Japan’s Takeda Sees $725 Million in Costs From R&D Revamp Jul 29 2016
Takeda Reports 1st Quarter 2016 Results with a Strong Start to the Year and Confidence in Management... Jul 29 2016
Seattle Genetics' (SGEN) Loss Narrower than Expected in Q2 Jul 27 2016
Takeda Pharmaceutical Co., Ltd. :TKPYY-US: Earnings Analysis: 2016 By the Numbers : July 26, 2016 Jul 26 2016
Takeda sets bidding deadline for chemical firm stake, CVC and Carlyle may bid -sources Jul 26 2016
Takeda sets bidding deadline for chemical firm stake, CVC and Carlyle may bid -sources Jul 26 2016
Takeda Said to Explore Sale of Chemicals Unit to Raise Cash Jul 21 2016
Stock Picker Wahei Takeda, Dubbed Japan’s Buffett, Dies at 83 Jul 21 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)